| BIOPHARMACEUTICAL-COMPANIES |
BIOPHARMACEUTICAL-COMPANIES |
90%
|
Accounts receivable primarily arise from testing services performed in the U.S. and are primarily with biopharmaceutical companies, healthcare organizations, employers, digital health platforms, conc… |
| CONCIERGE-MEDICINE-PRACTICES |
CONCIERGE-MEDICINE-PRACTICES |
90%
|
Accounts receivable primarily arise from testing services performed in the U.S. and are primarily with biopharmaceutical companies, healthcare organizations, employers, digital health platforms, conc… |
| DIGITAL-HEALTH-PLATFORMS |
DIGITAL-HEALTH-PLATFORMS |
90%
|
Accounts receivable primarily arise from testing services performed in the U.S. and are primarily with biopharmaceutical companies, healthcare organizations, employers, digital health platforms, conc… |
| EMPLOYERS |
EMPLOYERS |
90%
|
Accounts receivable primarily arise from testing services performed in the U.S. and are primarily with biopharmaceutical companies, healthcare organizations, employers, digital health platforms, conc… |
| HEALTHCARE-ORGANIZATIONS |
HEALTHCARE-ORGANIZATIONS |
90%
|
Accounts receivable primarily arise from testing services performed in the U.S. and are primarily with biopharmaceutical companies, healthcare organizations, employers, digital health platforms, conc… |
| INDIVIDUALS |
INDIVIDUALS |
90%
|
Accounts receivable primarily arise from testing services performed in the U.S. and are primarily with biopharmaceutical companies, healthcare organizations, employers, digital health platforms, conc… |
| ABBOTT-LABORATORIES |
ABBOTT-LABORATORIES |
85%
|
Exact Sciences Corporation (recently announced to be acquired by Abbott Laboratories) |
| ABT |
Abbott Laboratories |
85%
|
Reciprocal relationship from ABT graph: Reciprocal relationship from GRAL graph: Reciprocal relationship from ABT graph: Reciprocal relationship from GRAL graph: Reciprocal relationship from ABT grap… |
| EXACT-SCIENCES-CORPORATION |
EXACT-SCIENCES-CORPORATION |
85%
|
There are market participants in the cancer detection space both in the United States and abroad, including Exact Sciences Corporation (recently announced to be acquired by Abbott Laboratories) |
| ABT |
Abbott Laboratories |
72%
|
ess tests, operate our laboratory, delay our clinical studies, and damage our relationships with our customers. We could also be exposed to potential lawsuits, liability claims, reputational impact, … |
| BNR |
Burning Rock Biotech Limited |
72%
|
ess tests, operate our laboratory, delay our clinical studies, and damage our relationships with our customers. We could also be exposed to potential lawsuits, liability claims, reputational impact, … |
| BNR |
Burning Rock Biotech Limited |
72%
|
Reciprocal relationship from BNR graph: Reciprocal relationship from GRAL graph: Reciprocal relationship from BNR graph: Reciprocal relationship from GRAL graph: Reciprocal relationship from BNR grap… |
| EXAS |
Exact Sciences Corp |
72%
|
Reciprocal relationship from EXAS graph: Reciprocal relationship from GRAL graph: Reciprocal relationship from EXAS graph: Reciprocal relationship from GRAL graph: ess tests, operate our laboratory, … |
| EXAS |
Exact Sciences Corp |
72%
|
ess tests, operate our laboratory, delay our clinical studies, and damage our relationships with our customers. We could also be exposed to potential lawsuits, liability claims, reputational impact, … |
| GH |
Guardant Health, Inc. |
72%
|
ess tests, operate our laboratory, delay our clinical studies, and damage our relationships with our customers. We could also be exposed to potential lawsuits, liability claims, reputational impact, … |
| GH |
Guardant Health, Inc. |
72%
|
Reciprocal relationship from GH graph: Reciprocal relationship from GRAL graph: ess tests, operate our laboratory, delay our clinical studies, and damage our relationships with our customers. We coul… |
| TEM |
Tempus AI, Inc. |
72%
|
Reciprocal relationship from TEM graph: Reciprocal relationship from GRAL graph: ess tests, operate our laboratory, delay our clinical studies, and damage our relationships with our customers. We cou… |
| TEM |
Tempus AI, Inc. |
72%
|
ess tests, operate our laboratory, delay our clinical studies, and damage our relationships with our customers. We could also be exposed to potential lawsuits, liability claims, reputational impact, … |
| ALICE-CORPORATION-PTY-LTD |
ALICE-CORPORATION-PTY-LTD |
62%
|
tions, and permitting requirements, including those governing laboratory procedures; the generation, labeling, handling, use, storage, transport, treatment, and disposal of hazardous and regulated ma… |
| BUSINESS-GROUP |
BUSINESS-GROUP |
62%
|
rategy. We believe we currently have the largest share of the market for MCED testing, and we continue to build the key components of our commercial infrastructure and capabilities that are required … |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
e expect that the royalty payments we will make to Illumina in the foreseeable future will result in a 7% royalty rate. The royalty obligation is currently suspended until December 24, 2026 or any ea… |
